Bellevue Life Sciences Acquisition Corp.
BLAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $3,525 | $1,831 | $35 | $3 |
| SG&A Expenses | $3,525 | $1,831 | $35 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,525 | $1,831 | $35 | $3 |
| Operating Income | -$3,525 | -$1,831 | -$35 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,409 | $2,775 | $0 | $0 |
| Pre-Tax Income | -$2,115 | $945 | -$35 | -$3 |
| Tax Expense | -$296 | $541 | $0 | $0 |
| Net Income | -$2,411 | $404 | -$35 | -$3 |
| % Margin | – | – | – | – |
| EPS | -0.54 | 0.072 | -0.004 | -0 |
| % Growth | -852.1% | 1,941% | -875% | – |
| EPS Diluted | -0.54 | 0.072 | -0.004 | -0 |
| Weighted Avg Shares Out | 4,482 | 7,688 | 9,055 | 7,930 |
| Weighted Avg Shares Out Dil | 4,482 | 7,720 | 9,055 | 7,930 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $0 | $0 |
| Interest Expense | -$43 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2,775 | $228 | $237 |
| EBITDA | -$3,525 | $3,720 | $193 | $233 |
| % Margin | – | – | – | – |